注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Seres Therapeutics Inc是一家微生物学治疗平台公司。该公司致力于开发一类生物药物,旨在通过调节微生物组来治疗疾病,通过将被破坏的微生物组的功能修复到非疾病状态来恢复健康。该公司的主要候选产品SER-10旨在减少艰难梭菌感染(CDI)的进一步复发。它还在开发专门针对感染和抗菌素耐药性的治疗药物SER-155。SER-155是一种由培养的细菌组成的微生物组治疗候选药物,旨在降低接受异基因造血干细胞移植(allo-HSCT)患者的胃肠道感染、血流感染和移植物抗宿主病(GvHD)的发生率。此外,该公司正在利用其微生物组治疗平台开发SER-287和SER-301,以治疗溃疡性结肠炎(UC)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Richard N. Kender | 68 | 2014 | Independent Director |
Eric D. Shaff | 48 | 2014 | President, CEO & Director |
Dennis Arthur Ausiello | 79 | 2015 | Independent Director |
Mark H. Wilcox | - | 2015 | Member of Scientific Advisory Board |
Andrew Goodman | - | - | Member of Scientific Advisory Board |
Curtis Huttenhower | - | - | Member of Scientific Advisory Board |
Willard H. Dere | 70 | 2017 | Independent Director |
Kurt C. Graves | 56 | 2015 | Independent Director |
Stephen A. Berenson | 63 | 2019 | Independent Chairman |
Claire M. Fraser-Liggett | 69 | 2023 | Independent Director |
Paul R. Biondi | 54 | 2020 | Independent Director |
Robert Jenq | - | - | Member of Scientific Advisory Board |
Marcel R.M. van den Brink | - | - | Member of Scientific Advisory Board |
Elhanan Borenstein | - | - | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核